Company Overview

REGENERON PHARMACEUTICALS, INC.

REGN
Annual
Revenue vs. Cost of Revenue
Revenue Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses Operating Income
Net Income
Net Income
Revenue
14,343M
2025 FY
Net Income
4,505M
2025 FY
Shares Outstanding
105M
2025 FY
EPS
43.07USD
2025 FY
Company Information
SIC Code
2834
CIK Code
872589
Exchange
Nasdaq
Location
US